Basaglar Kwik Pen

Composition of Basaglar Kwik Pen

Basaglar Kwik Pen contains Insulin glargine 100 IU/mL (3 mL prefilled pen). It belongs to the Long-acting insulin analogue (basal insulin) class of medicines.

Uses of Basaglar Kwik Pen

Treatment of diabetes mellitus to improve glycaemic control in adults and children where basal insulin is required (Type 1 diabetes as part of a basal-bolus regimen; Type 2 diabetes when oral agents are inadequate or insulin is indicated).

Key benefits

• Provides 24-hour basal insulin coverage
• Lowers fasting blood glucose
• Helps improve HbA1c control
• Once-daily dosing convenience
• Suitable for Type 1 and Type 2 diabetes as prescribed

How Basaglar Kwik Pen works

Insulin glargine is a long-acting basal insulin analogue. After subcutaneous injection it forms microprecipitates that slowly release insulin, providing a near-constant insulin level for about 24 hours to reduce fasting and between-meal blood glucose.

How to take Basaglar Kwik Pen

For subcutaneous injection only using the pen, once daily at the same time each day. Inject into abdomen, thigh or upper arm and rotate injection sites; do not inject into a vein or muscle. Can be taken with or without food; dose is individualized by the doctor—do not change dose/brand without medical advice.

Take it exactly as your doctor prescribed. Do not change the dose or stop early on your own.

Missed dose and overdose

If you miss a dose

Take the missed dose of Basaglar Kwik Pen as soon as you remember. If it is almost time for the next dose, skip the missed one and carry on with the usual schedule. Do not take two doses together to make up for a missed dose.

If you take too much

Taking more Basaglar Kwik Pen than prescribed can be harmful. If you suspect an overdose, contact a doctor or go to the nearest emergency department at once, and carry the pack or strip with you. In India the emergency number is 112.

Side effects of Basaglar Kwik Pen

Most side effects of Basaglar Kwik Pen are mild and settle as the body adjusts. Reported side effects include:

• Hypoglycaemia
• injection site reactions (pain/redness/swelling/itching)
• lipodystrophy
• weight gain
• oedema
• rash
• pruritus

Stop the medicine and seek help immediately for a rash, swelling of the face or lips, wheezing or difficulty breathing. Tell your doctor about any side effect that persists or worries you.

Safety advice for Basaglar Kwik Pen

Warnings and precautions

Risk of hypoglycaemia—monitor blood glucose and carry fast-acting sugar. Do not use during episodes of hypoglycaemia. Not for IV use or insulin pump use; do not mix or dilute with other insulins unless specifically advised. Use caution in renal/hepatic impairment, elderly, irregular meals, increased physical activity, or during illness; dose adjustment may be required. Rotate injection sites to reduce lipodystrophy. Seek urgent care for signs of allergy (wheezing, swelling, generalized rash) or severe hypoglycaemia.

Interactions with other medicines

Other antidiabetic medicines (additive hypoglycaemia), beta-blockers (may mask hypoglycaemia symptoms), ACE inhibitors, salicylates, MAO inhibitors (increase hypoglycaemia risk), corticosteroids, thiazide/loop diuretics, thyroid hormones, sympathomimetics, oral contraceptives (may increase blood glucose), alcohol (may increase or decrease glucose), pioglitazone (risk of fluid retention/heart failure when used with insulin).

How to store Basaglar Kwik Pen

Store unopened pens in a refrigerator at 2–8°C; do not freeze; protect from light. After first use, keep at room temperature (generally below 25–30°C as per label) away from heat/light; keep cap on; do not refrigerate in-use pen; discard after the in-use period stated on pack (commonly 28 days).

Manufacturer and class

Manufacturer:

CIPLA LIMITED

Therapeutic class:

Antidiabetic

Drug class:

Long-acting insulin analogue (basal insulin)